

## **e-NICOTINE TECHNOLOGY TO PRESENT CLINICAL DATA AT THE SOCIETY FOR RESEARCH ON NICOTINE AND TOBACCO**

### *Data Show Rapid Smoking Urge Reduction Using a Novel Nicotine Aerosol*

CHAPEL HILL, NC (January 31, 2014) – e-Nicotine Technology (eNT) announced today that it will be presenting its initial clinical research results in a poster entitled “*Achieving Rapid Smoking Urge Relief and Nicotine Pharmacokinetics Through the Manipulation of the Particle Size of a Condensation Aerosol of Nicotine and Propylene Glycol*” at the 20<sup>th</sup> Annual Meeting for the Society for Research on Nicotine and Tobacco being held from February 5-8<sup>th</sup> this year in Seattle, WA.

Using its proprietary thermal drug delivery technology, eNT has successfully created a 1-3 micron aerosol of nicotine and propylene glycol, targeted to produce more rapid smoking urge relief while using less than half the nicotine of current products on the market, including both e-cigarettes and Nicotine Replacement Therapies. "Our data shows that we are able to reduce smoking urges by more than 70% within 1-minute, setting a new standard for smoking urge relief" said Dr. Michael Hufford, Chief Medical Officer at eNT.

"Since the company's founding a little over a year ago, we have completed and manufactured our clinical device that will have the same components as our commercial product, completed a multi-part clinical trial in over 90 smokers, had a meeting with the FDA's Center For Tobacco Products, filed multiple US and foreign patents, and have raised \$4MM in our Series A round based on our technology and experienced management team", said Jeffrey Williams, President and CEO. "What an exciting time for improving the health of smokers. With so much innovation yet to come, we are excited to be at the forefront of this public health transformation", said Don Watkins Chairman of the Board at eNT.

### **About e-Nicotine Technology**

eNT is a company committed to reducing the harm associated with tobacco products by combining clean nicotine aerosols for inhalation with empowering e-health tools. eNT is developing an electronic nicotine delivery device that produces a condensation aerosol of nicotine using its proprietary thermal drug delivery technology. The eNT platform delivers the right dose of nicotine using the right sized aerosol particles for deep lung delivery.

For more information on eNT, its products, and other inquiries, please contact: Justin Bingham at +1.801.502.3458 or [jbingham@enicotinetechnology.com](mailto:jbingham@enicotinetechnology.com), [www.enicotinetechnology.com](http://www.enicotinetechnology.com).